In conclusion, the combination of PD-1/PD-L1 inhibitors with CTLA-4 inhibitors presents a complex landscape regarding thromboembolic risk, influenced by both the therapeutic regimen and the underlying tumor type. This evidence concerns the gene PDCD1 and neoplasm.